araag2/HINT huggingface dataset:
Clinical trial NCT00442936 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: telcagepant potassium 150 mg, telcagepant potassium 300 mg, zolmitriptan 5 mg, placebo to telcagepant 150 mg, placebo to tecagepant 300 mg, placebo to zolmitriptan 5 mg, rescue medication
SMILES: [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Has at least 1 year history of migraine (with or without aura)

          -  Females of child bearing potential must use acceptable contraception throughout trial.

        Exclusion Criteria:

          -  Is pregnant/breast-feeding (or is a female expecting to conceive during study period)

          -  Has history or evidence of stroke/transient ischemic attacks, heart disease, coronary
             artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled
             hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency
             virus (HIV) disease

          -  Has major depression, other pain syndromes that might interfere with study
             assessments, psychiatric conditions, dementia, or significant neurological disorders
             (other than migraine)

          -  Has a history of gastric, or small intestinal surgery, or has a disease that causes
             malabsorption

          -  Has a history of cancer within the last 5 years.
Clinical trial NCT00443703 (phase 3, status: terminated)
Conditions: hiv infection
ICD codes: Z21
Drugs: mk0518 (raltegravir), comparator: kaletra™ (lopinavir (+) ritonavir ), comparator: placebo, comparator: placebo
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Reason stopped: 
    primary efficacy analysis at week 24 did not demonstrate non-inferiority of raltegravir versus
    lopinavir (+) ritonavir
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is at least 18 years of age

          -  Patient is Human Immunodeficiency Virus (HIV) positive

          -  Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) <50
             copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen

          -  Patient has been on a KALETRA based regimen for at least 3 months without a change in
             background antiretroviral therapy

          -  Patient has no documentation of HIV RNA >50 copies/mL for at least 3 months while on
             the KALETRA based regimen

        Exclusion Criteria:

          -  Patient is or plans to become pregnant, or nursing a child

          -  Patient plans to donate eggs or impregnate/donate sperm

          -  Patient is receiving Stavudine (d4T) as a component of the background antiretroviral
             therapy

          -  Patient is currently receiving a second protease inhibitor in addition to KALETRA

          -  Patient is currently receiving, or has received in the past twelve weeks, treatment
             for the management of elevated lipids

          -  Patient has used another experimental HIV-integrase inhibitor

          -  Patient has a current (active) diagnosis of acute hepatitis due to any cause

          -  Patient has used systemic immunosuppressive therapy within one month prior to
             treatment in this study
Clinical trial NCT00443729 (phase 3, status: terminated)
Conditions: hiv infection
ICD codes: Z21
Drugs: comparator: raltegravir, comparator: placebo, comparator: lopinavir (+) ritonavir, comparator: placebo
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, CN(C)C(=N)NC(N)=N, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CN(C)C(=N)NC(N)=N
Reason stopped: 
    primary efficacy analysis at week 24 did not demonstrate non-inferiority of raltegravir versus
    lopinavir (+) ritonavir
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is at least 18 years of age

          -  Patient is human immunodeficiency virus (HIV) positive

          -  Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) <50
             copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen

          -  Patient has been on a KALETRA based regimen for at least 3 months without a change in
             background antiretroviral therapy

          -  Patient has no documentation of HIV RNA >50 copies/mL for at least 3 months while on
             the KALETRA based regimen

        Exclusion Criteria:

          -  Patient is or plans to become pregnant, or is nursing a child

          -  Patient plans to donate eggs or impregnate/donate sperm

          -  Patient is receiving Stavudine (d4T) as a component of the background antiretroviral
             therapy

          -  Patient is currently receiving a second protease inhibitor in addition to KALETRA

          -  Patient is currently receiving, or has received in the past twelve weeks, treatment
             for the management of elevated lipids

          -  Patient has used another experimental HIV-integrase inhibitor

          -  Patient has a current (active) diagnosis of acute hepatitis due to any cause
Clinical trial NCT01231464 (phase 3, status: completed)
Conditions: rhinitis, allergic, perennial, allergic rhinitis
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1, J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: fluticasone furoate nasal spray, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects can be enrolled when meeting all criteria as below.

               1. Chinese adolescent and adult (male or eligible female) outpatients with the age
                  of >=12 years

               2. Confirmative diagnosis of IAR or PER (as definitions from ARIA 2008 and the
                  coming effective Chinese AR management guideline ), by medical history, symptoms,
                  skin prick tests (SPTs)

               3. Subject must be symptomatic at screening and willing to maintain same environment
                  throughout the study

               4. Ability to comply with study procedures

               5. Literate

        Exclusion Criteria:

          -  Subjects should be excluded when meeting one of criteria as below.

               1. Having complications of nasal disease, or vasomotor rhinitis, rhinitis with
                  eosinophilia, or drug rhinitis

               2. Having complications of bacterial/viral infection of upper respiratory tract

               3. Having significant systemic diseases

               4. History of hypersensitivity to steroids and ingredients

               5. Pregnant women or under lactation

               6. Patients who started, discontinued or changed dose of desensitization therapy
                  within 30 days before visit 1

               7. Patients planning to travel outside the region

               8. Patients judged to be inappropriate by investigators

               9. Patients who participated in another study within 4 months before screening

              10. Patients who could not withdraw drugs during screening period or secure
                  withdrawal period until the initiation day of administration, e.g.

                    1. allergy medications

                    2. other medications that may affect allergic rhinitis or its symptoms

                    3. any medications that significantly inhibit CYP3A4, including ritonavir and
                       ketoconazole
Clinical trial NCT01601990 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo group(once daily), lc15-0444 50mg qd
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with Type 2 Diabetes Mellitus

          2. Adults between 18 and 75 of age

          3. Patients with HbA1c between 7 % and 11 %

          4. Patient who had not received any diabetic medications within 6 weeks from screening

          5. Patients who signed on the consent form after informed on the object, method, and
             risks of the clinical study

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes

          2. Patients who were taking or needed to take any drugs which may affect the control of
             blood glucose significantly (ex. glucocorticoids)

          3. Patients who had experienced myocardial infarction, unstable angina or prior history
             of coronary artery bypass surgery within 6 months prior to screening, or patients with
             arrhythmia requiring treatment

          4. Patients with NYHA class II-IV congestive heart failure

          5. Patients with history of hepatic cirrhosis

          6. Patients with renal failure or whose creatinine clearance was less than 60mL/min

          7. Patients with dysfunctional thyroid gland (with abnormal level of TSH)

          8. Patients with ALT, AST or CPK exceeding 2.5 times of the upper limit of the normal
             range

          9. Patients with BMI below 20 kg/m2 or exceeding 40 kg/m2

         10. Patients with history of asthma or major skin allergy

         11. Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.

         12. Patients with history of hypersensitivity to metformin or biguanides.

         13. Patients who took sodium channel blockers in the last 6 weeks prior to Visit 1.

         14. Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or
             who took thiazolidinediones (Glitazone) in the last 6 months prior to Visit 1.

         15. Patients with other reasons who the investigator decided not to be eligible for the
             study
Clinical trial NCT00372060 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: sitagliptin phosphate (mk0431), comparator: pioglitazone, comparator: placebo (unspecified)
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients Have Type 2 Diabetes Mellitus

          -  On Diet/Exercise Therapy And Pioglitazone As Monotherapy

        Exclusion Criteria:

          -  Patients Have Type 1 Diabetes Mellitus
Clinical trial NCT00550953 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan+amlodipine, telmisartan
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Essential hypertensive patients who satisfying non-responder criteria

          2. Male or Female

          3. Age 20 years or older

          4. Outpatient

        Exclusion Criteria:

          1. Taking four or more anti-hypertensive medications

          2. Secondary hypertension

          3. Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic
             blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP < 90 mmHg
             at Visit 3.

          4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias

          5. Congestive heart failure patients with the New York Heart Association (NYHA)
             functional class III-IV

          6. History of myocardial infarction or cardiac surgery within last 6 months

          7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI)
             within last 3 months

          8. History of unstable angina within last 3 months

          9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve

         10. History of stroke or transient ischemic attack within last 6 months

         11. History of sudden exacerbation of renal function with angiotensin II receptor blockers
             (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal
             transplant or post-nephrectomy

         12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE
             inhibitors

         13. Known hypersensitivity to any component of the investigational drug , or a known
             hypersensitivity to dihydropyridine -derived drugs

         14. Hepatic and/or renal dysfunction

         15. Diagnosed biliary atresia or cholestasis

         16. Hyperkalemia

         17. Dehydration

         18. Sodium deficiency

         19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs
             (NSAIDs)

         20. Patients who cannot change to the restricted administration and dosage during study
             period

         21. Pre-menopausal women who meet any one of the following 1 - 3:

               -  Pregnant or possibly pregnant (1)

               -  Nursing (2)

               -  Desire to become pregnant during study period (3)

         22. Drug or alcohol dependency

         23. Complication of malignant tumour or a disease requiring immunosuppressants

         24. Compliance of < 80% or > 120% during the run-in period

         25. Receiving any investigational therapy within 3 months

         26. Judged to be inappropriate by the investigator or the sub-investigator
Clinical trial NCT00699751 (phase 3, status: completed)
Conditions: hormone refractory prostate cancer, bone metastases
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: radium-223 dichloride (xofigo, bay88-8223), placebo, best standard of care (bsoc)
SMILES: Cl[223Ra]Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Known hormone refractory disease

          -  Multiple skeletal metastases (≥ 2 hot spots) on bone scintigraphy

          -  No intention to use cytotoxic chemotherapy within the next 6 months

          -  Either regular (not occasional) analgesic medication use for cancer related bone pain
             or treatment with EBRT (External Beam Radiation Therapy) for bone pain

        Exclusion Criteria:

          -  Treatment with an investigational drug within previous 4 weeks, or planned during the
             treatment period

          -  Eligible for first course of docetaxel, i.e. patients who are fit enough, willing and
             where docetaxel is available

          -  Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the
             treatment period, or failure to recover from adverse events due to cytotoxic
             chemotherapy administered more than 4 weeks ago

          -  Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for
             the treatment of bony metastases within previous 24 weeks

          -  Other malignancy treated within the last 5 years (except non-melanoma skin cancer or
             low-grade superficial bladder cancer)

          -  History of visceral metastasis, or visceral metastases as assessed by abdominal/pelvic
             CT or chest x-ray within previous 8 weeks
Clinical trial NCT00420199 (phase 3, status: completed)
Conditions: active rheumatoid arthritis
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Disease activity as defined by a Disease Activity Score 28-C-Reactive Protein (CRP)
             >3.2 or >6 swollen and ≥6 tender joints and CRP greater than the upper limit of normal

          -  At least 1 erosion in hands/wrists or positive anticyclic citrullinated peptides or
             rheumatoid factor

          -  Clinically detectable synovitis of at least 1 wrist/ankle at screening and baseline

          -  Participants must have been treated with methotrexate, on a weekly dose of at least 15
             mg or a maximum tolerated dose (such as, 10 mg weekly) for at least 3 months before
             screening. Dose of methotrexate must be stable for at least 28 days prior to the first
             study dose (Day 1)
Clinical trial NCT01076075 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: placebo to pioglitazone, comparator: placebo to sitagliptin, comparator: pioglitazone, glimepiride or gliclazide, metformin, pioglitazone rescue therapy
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Hemoglobin A1C of ≥7.5% and ≤10.5%

          -  Currently taking a stable dose of metformin (at least 1500 mg/day) and either
             glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered
             dose) for at least 10 weeks prior to study start

          -  Male, or a female who is highly unlikely to conceive

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or ketoacidosis

          -  Taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin) or a
             glucagon-like peptide-1 (GLP-1) mimetic (such as exenatide or liraglutide) or required
             insulin therapy within 12 weeks prior to study start

          -  On a weight loss program not in the maintenance phase or on a weight loss medication

          -  History of liver disease, heart failure, heart disease, stroke, high blood pressure,
             blood disorders, or cancer

          -  HIV positive

          -  Pregnant
Clinical trial NCT00518713 (phase 3, status: completed)
Conditions: epilepsy, epilepsy, generalized, seizures
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.311, G40.319, G40.411, G40.419, G40.301, G40.309, G40.401, G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: clobazam low dose, clobazam medium dose, clobazam high dose, placebo
SMILES: CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O, CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O, CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have been <11 years of age at the onset of LGS.

          -  Patient must have LGS.

          -  Patient must be on at least 1 AED.

          -  Parent or caregiver must be able to keep an accurate seizure diary.

        Exclusion Criteria:

          -  Etiology of patient's seizures is a progressive neurologic disease. Patients with
             tuberous sclerosis will not be excluded from study participation, unless there is a
             progressive tumor.

          -  Patient has had an episode of status epilepticus within 12 weeks of baseline.

          -  Patient has had an anoxic episode requiring resuscitation within 6 months of
             screening.

          -  Patient has a clinically significant history of an allergic reaction or significant
             sensitivity to benzodiazepines.

          -  Patient is taking more than 3 concurrent AEDs.

          -  Patient has been on the ketogenic diet for less than 30 days prior to screening or
             suffers from frequent stooling.

          -  If the patient has a Vagal Nerve Stimulator (VNS), the settings have not been stable
             for at least 30 days prior to screening.

          -  Patient has taken corticotropins in the 6 months prior to screening.

          -  Patient is currently taking long-term systemic steroids (excluding inhaled mediation
             for asthma treatment) or any other daily medication known to exacerbate epilepsy. An
             exception will be made of prophylactic medication, for example, for idiopathic
             nephrotic syndrome or asthma.

          -  If the patient is taking felbamate, has been taking it for less than 1 year prior to
             screening.

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT00699426 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: nexium, nexium, placebo+placebo
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (WHO criteria) treated with metformin and/or sulfonylureas or diet

          -  Males and females between 40 and 70 years

          -  HbA1c between 6,0-10,0

          -  Diabetes duration > 1 year

        Exclusion Criteria:

          -  Kidney disease (s-creatinine above the upper limit of normal range).

          -  Liver disease (ALAT increase > 3 times the upper limit of the normal range of ALAT).

          -  Macroalbuminuria (urinary albumin excretion of > 300 mg/day).

          -  Heart failure(NYHA class lll or lV)

          -  Severe neuropathy (symptoms + vibration perception threshold > 50 measured by
             biothesiometer.)

          -  Neutropenia (neutrophil count<2.0x10/l) or anemia (hemoglobin<8mM for men or <7mM for
             women.

          -  Alcohol abuse

          -  Drug abuse

          -  Severe organic or metabolic diseases including cancer

          -  C-peptide< 0,3 pmol/l

          -  Medicine interaction

          -  Treatment with insulin

          -  PPI or other medications for ulcus diseases

          -  Treatment with warfarin or other coumarin derivations

          -  Pregnant or breastfeeding women

          -  Allergy to medication used in the study

          -  Participants may not participate in another clinical intervention trial